Cargando…

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia

Small‐molecule‐induced degradation of mutant Bcr‐Abl1 provides a potential approach to overcome Bcr‐Abl1 tyrosine kinase inhibitor (TKI)‐resistant chronic myeloid leukemia (CML). Our previous study reported that a synthetic steroidal glycoside SBF‐1 showed remarkable anti‐CML activity by inducing th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elgehama, Ahmed, Wang, Yixuan, Yu, Ying, Zhou, Lin, Chen, Zhixiu, Wang, Liwei, Sun, Lijun, Gao, Jian, Yu, Biao, Shen, Yan, Xu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807508/ https://www.ncbi.nlm.nih.gov/pubmed/36086954 http://dx.doi.org/10.1111/cas.15580

Ejemplares similares

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia
por: Yang, Ke, et al.
Publicado: (2021)

Expression of chronic myeloid leukemia oncogenes BCR-ABL (P210) and BCR-ABL (T315I) affect cellular and humoral innate immunity in Drosophila melanogaster
por: Abubaker, Dana, et al.
Publicado: (2022)

Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2018)

BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
por: Cai, Zhimei, et al.
Publicado: (2020)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

p210(BCR‐ABL1)‐ Chronic myeloid leukemia presents with monocytosis
por: Wang, Xiaofei, et al.
Publicado: (2020)

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
por: Khateb, Mamduh, et al.
Publicado: (2012)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
por: Jiang, Liang, et al.
Publicado: (2021)

Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
por: Yu, Chuanjiang, et al.
Publicado: (2020)

Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A
por: Xu, Yun, et al.
Publicado: (2023)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
por: Molica, Matteo, et al.
Publicado: (2020)

Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case
por: Al-Achkar, Walid, et al.
Publicado: (2014)

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
por: Gao, Congying, et al.
Publicado: (2023)

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
por: Montecchini, Oksana, et al.
Publicado: (2021)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
por: Zabriskie, Matthew S., et al.
Publicado: (2015)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
por: Zhang, Hao, et al.
Publicado: (2022)

The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
por: Grassi, Susanna, et al.
Publicado: (2019)

Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish
por: Xu, Mengchang, et al.
Publicado: (2020)

Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
por: Smith, Brittany M., et al.
Publicado: (2021)

Initial Rate of BCR::ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia
por: Branford, Susan
Publicado: (2022)

NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature
por: Catalano, Gianfranco, et al.
Publicado: (2020)

The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants
por: Ye, Wu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_27hikto9diego0otcfbij57e81